Sharps Technology Inc Stock Price, News & Analysis

Sharps Technology (NASDAQ: STSS), a medical device and pharmaceutical packaging company specializing in smart safety syringe products, announced that CEO Robert Hayes will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. The company recently achieved a significant milestone by initiating its first commercial shipments under three customer orders from previously announced purchase agreements, marking its transition to revenue-generating operations. The products are being manufactured at Sharps' upgraded Hungarian facility, which has been enhanced for high-volume production. The Investor Summit is focused on small- and micro-cap stocks, providing a platform for investors to engage with management teams from emerging companies and gain insights from industry experts.

Sharps Technology (NASDAQ: STSS) has initiated commercial shipments across three customer orders, marking its transition to a revenue-generating company. The company delivered its first commercial order of SoloGard syringes under a $50 million supply agreement with a U.S.-based IV flushing solutions leader, starting with a $400,000 order as part of a five-year contract for up to 500 million syringes. Additionally, Sharps shipped SecureGard smart safety syringes worth $100,000 to a Hungarian vaccine provider and commenced delivery of 200,000 units of 1mL low dead space syringes to a Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies. The total initial purchase commitments amount to approximately $500,000. All products are manufactured at the company's upgraded Hungary-based facility, which features advanced molding and automation technologies to support high-volume production.

Sharps Technology (NASDAQ: STSS), a medical device and pharmaceutical packaging company specializing in smart-safety syringe products, announced that CEO Robert Hayes will present at the Aegis Capital Corp. 2025 Virtual Conference on May 22, 2025, at 1:00 p.m. ET.

The company focuses on ultra-low waste capabilities with passive and active safety features in their syringe technologies. Sharps also offers products with specialized copolymer technology for the prefillable syringe market segment and operates a manufacturing facility in Hungary.

Sharps Technology (NASDAQ: STSS) has secured a $100,000 purchase order for SecureGard™ syringes from a Hungarian vaccine provider, along with an initial qualification order for DisGard™ single-use Sharps Recovery System. Combined with a recently announced $400,000 SoloGard™ order, the company's Q2 orders total approximately $500,000. The SoloGard order is part of a broader $50 million agreement with a U.S. company. This milestone marks Sharps' transition to a commercial-stage company. The company manufactures SecureGard, SoloGard, and DisGard products at their Hungarian facility, where they maintain inventory to meet current and future demand. SecureGard features include low dead space, manual retraction, latex-free composition, and breakaway plunger, available in 1ml, 3ml, and 5ml capacities.

Sharps Technology has received a $400,000 initial purchase order from a leading U.S. IV flushing solutions provider, marking its first commercial revenue under a previously announced $50 million supply agreement. The deal, established in July 2024, involves delivering approximately 500 million customized 10mL SoloGard syringes over five years.

The company's Hungarian manufacturing facility is ready to fulfill these first orders, with strategic investments made in advanced production technology through partnerships with Husky Medical Molds and BBS Automation. These collaborations aim to streamline production processes and enhance manufacturing efficiency.

CEO Robert Hayes describes this as a transformative moment for the company, signaling the transition from agreement to execution phase. The company expects to scale up production volume in coming quarters, leveraging precision molding and advanced automation to meet the growing demand under this significant contract.

Sharps Technology (NASDAQ: STSS) has announced a 1-for-300 reverse stock split of its common stock, effective April 27, 2025, at 11:59 PM Eastern Time. The company's stock will begin trading on a post-reverse split basis on April 28, 2025, maintaining its current symbol 'STSS' on the Nasdaq Capital Market.

The primary purpose of this reverse split is to ensure compliance with Nasdaq's minimum bid price requirement for continued listing. As part of this action, the company's authorized common shares will be reduced from 500,000,000 to 1,666,667. The Board of Directors implemented this decision without shareholder approval, as permitted under Nevada Revised Statutes Section 78.207, since it provides for a proportionate reduction in both authorized and outstanding shares.

Sharps Technology (Nasdaq: STSS) has issued a important reminder to shareholders to vote in favor of a proposed reverse stock split at the upcoming shareholder meeting on March 28, 2025. The vote is essential to maintain STSS's Nasdaq listing and prevent delisting to OTC Markets.

The special meeting, scheduled for 10:00 a.m. Eastern Time, requires shareholder approval to meet Nasdaq's minimum bid price requirement of $1.00 per share. Shareholders of record as of January 29, 2025, are eligible to vote. The company's Board of Directors unanimously supports the proposal.

CEO Robert M. Hayes emphasizes that maintaining the Nasdaq listing is vital for ensuring strong liquidity and broad investor access. If approved, the reverse stock split will decrease the number of outstanding shares while increasing the price per share, with shareholders maintaining their same percentage interest in the company.

Shareholders requiring assistance can contact Advantage Proxy at (877) 870-8565 or ksmith@advantageproxy.com. The proxy statement details are available on the SEC website and at virtualshareholdermeeting.com/STSS2025SM.

Sharps Technology (STSS) has provided a corporate update following its recent $20 million capital raise in January 2025. The company has strengthened its balance sheet, eliminated debt, and is advancing its operations in Hungary through key agreements.

The company has a five-year agreement with a U.S. medical products supplier for customized 10mL SoloGard syringes, targeting production of 500 million units worth approximately $50 million. Revenue generation is expected to begin in H2 2025.

STSS is also progressing with SecureGard safety syringe deliveries to a European distributor serving Poland, Slovakia, and Czech Republic, with qualification processes underway at Penta Hospitals International, which operates 34 hospitals and 31 outpatient clinics in Central and Eastern Europe.

The company is expanding its Hungarian manufacturing operations with advanced machinery and workforce enhancement, while continuing negotiations for manufacturing capabilities in South Carolina.

Sharps Technology (NASDAQ: STSS) has closed its upsized underwritten public offering, raising $20.0 million in gross proceeds. The offering comprised 14,285,714 Common Units priced at $1.40 per unit (or $1.3999 for Pre-Funded Units). Each unit consists of one share of Common Stock (or Pre-Funded Warrant), one Series A Warrant, and one Series B Warrant.

Both Series A and B Warrants have an exercise price of $1.75. Series A Warrants expire in 60 months while Series B Warrants expire in 30 months after stockholder approval. The underwriter, Aegis Capital Corp., exercised its over-allotment option for 2,142,857 Series A Warrants and 2,142,857 Series B Warrants.